PIK3CA and adenocarcinoma: To demonstrate the utility of our model to test potential therapies for colorectal cancer, we selected the PI3Kα-selective inhibitor, BYL719, to treat subcutaneously transplanted Pik3ca-mutant adenocarcinomas.